BofA Securities resumed coverage on Dr. Reddy's
$RDY
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities resumed coverage of Dr. Reddy's with a rating of Neutral
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/5/2025 | $16.89 | Hold → Buy | HSBC Securities |
12/19/2024 | Buy → Neutral | Nomura | |
1/11/2024 | Buy → Underperform | Jefferies | |
8/29/2023 | Buy → Hold | HSBC Securities | |
5/18/2023 | Outperform → Mkt Perform | Bernstein | |
3/17/2023 | Neutral → Buy | BofA Securities | |
1/30/2023 | Underweight | JP Morgan | |
11/14/2022 | Neutral → Underperform | Credit Suisse |
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)